Monday, November 9, 2026

USD/EUR Bullish By 1% In The Last 21 Sessions

ViaNews Editorial Team

February 12, 2024

USD/EUR Bullish By 1% In The Last 21 Sessions

(VIANEWS) - USD/EUR (USDEUR) has been up by 1.91% for the last 21 sessions. At 15:12 EST on Monday, 12 February, USD/EUR (USDEUR) is $0.93.

USD/EUR's yearly highs and lows, it's 4.634% up from its 52-week low and 3.03% down from its 52-week high.

Volatility

USD/EUR's last week, last month's, and last quarter's current intraday variation average was 0.01%, 0.10%, and 0.32%, respectively.

USD/EUR's highest amplitude of average volatility was 0.17% (last week), 0.25% (last month), and 0.32% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, USD/EUR's Forex is considered to be overbought (>=80).

News about

  • Eur/usd advances to one-week top on softer usd, upside potential seems limited. According to FXStreet on Monday, 12 February, "The EUR/USD pair loses traction following an early uptick to the 1.0800 mark, or over a one-week high on Monday and drops to a fresh daily low during the first half of the European session. ", "Apart from this, the underlying bullish sentiment across the global equity markets turns out to be another factor capping gains for the safe-haven buck and acts as a tailwind for the EUR/USD pair. "
  • Eur/usd gains ground near 1.0800, ZEW survey, US CPI data eyed. According to FXStreet on Monday, 12 February, "The EUR/USD pair attracts some buyers near 1.0800 during the early Asian trading hours on Monday. "
  • Eur/usd slumps amid ecb’s dovish signals ahead of US CPI. According to FXStreet on Monday, 12 February, "Over the weekend, comments by ECB's Governing Council Panetta fueled speculation that Lagarde and Co. might cut rates earlier than the US Federal Reserve (Fed), opening the door for further EUR/USD downside. ", "On the US, February's Consumer Price Index (CPI) figures could move the needle in the EUR/USD pair. "
  • Eur/usd price analysis: could test psychological barrier at 1.0800 ahead of 14-day EMA. According to FXStreet on Monday, 12 February, "On the downside, the EUR/USD pair has immediate support at the psychological level of 1.0750, with further support at the previous week's low of 1.0722, observed on February 6. ", "A firm break above the EMA could intensify upward momentum for the EUR/USD pair, targeting the 23.6% Fibonacci retracement level at 1.0821, along with the significant barrier at 1.0850. "
  • Eur/usd can find some support back above 1.0800 – ING. According to FXStreet on Monday, 12 February, "The holding pattern that EUR/USD has shown recently may well remain the norm in the coming weeks.", "We see some modest downside risks for the Dollar this week, and think EUR/USD can find some support back above 1.0800, although a return to the 1.0930/1.0950 area looks premature."

More news about USD/EUR (USDEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Cycle: Data Readouts, FDA Decisions and Capital-Allocation Shifts
From late October to January, mid-cap biotechs move through a dense run of events: ESMO and AHA/AASLD data presentations, Q3 earnings, and FDA PDUFA dates for ivonescimab (Nov 14) and lorundrostat (Dec 22). Alongside the regulatory news, companies are changing how they allocate capital: one lowered FY2026 R&D and SG&A guidance and pushed milestones into 2027, one authorized a $400M buyback, and one scheduled a delisting vote (EGM Nov 19, application Jan 25). Value is concentrating in a few binary regulatory and Phase 3 outcomes (Maritime-1 and ECLIPSE 2/3 readouts around Q1 2027), so sentiment is mixed.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,558 source documents archived
Query this data → isubstrate.com